Gilead, Gala­pa­gos claim PhI­Ib/III win for fil­go­tinib in ul­cer­a­tive col­i­tis — which pales in com­par­i­son to ri­vals

A cut of late-stage da­ta on one of Gilead’s high­est-pro­file ex­per­i­men­tal drugs be­fore remde­sivir made its come­back has thrust­ed the com­pa­ny back to the pre-pan­dem­ic mode of biotech — where claims of suc­cess­es are nec­es­sar­i­ly scru­ti­nized and don’t al­ways trans­late to stock gains.

Gilead and its part­ners at Gala­pa­gos char­ac­ter­ized the topline Phase IIb/III re­sults for fil­go­tinib, their oral JAK1 in­hibitor, in mod­er­ate­ly to se­vere­ly ac­tive ul­cer­a­tive col­i­tis as “pos­i­tive.” But a few para­graphs down, they not­ed that on­ly the 200 mg achieved the clean sweep across all pri­ma­ry end­points, while the 100 mg failed to in­duce clin­i­cal re­mis­sion at week 10.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.